Life Saving Drugs Program (LSDP) – Medicines reviews recommendations

This document outlines 51 recommendations from the Life Saving Drugs (LSDP) expert panel review.


LSDPEP – Medicines reviews recommendations

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date:
Date last updated:
Publication type:
Health sector

The independent review includes two 2 sections and eight 8 sub-sections of recommendations:

  1. Cross-program recommendations
  2. Medicine-specific recommendations
    • Fabry disease
    • Gaucher disease
    • Mucopolysaccharidosis type I (MPS I)
    • Mucopolysaccharidosis type II (MPS II)
    • Mucopolysaccharidosis type VI (MPS VI)
    • Pompe disease
    • Hereditary tyrosinaemia type I (HT1)
    • Paroxysmal nocturnal haemoglobinuria (PNH)

Help us improve

If you would like a response please use the enquiries form instead.